AdaptNK

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAdaptNK

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived

Mechanisms of ActionNatural killer cells stimulants

TargetsNot applicable

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesMasonic Cancer Center, University Of Minnesota

China Registration ClassN/A

Develop Information

Active CompaniesMasonic Cancer Center, University Of Minnesota

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A